<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: To assess the effect of an angiotensin receptor blocker (ARB) on serum <z:chebi fb="120" ids="26216">potassium</z:chebi> and the effect of a serum <z:chebi fb="120" ids="26216">potassium</z:chebi> change on renal outcomes in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We performed a post hoc analysis in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> participating in the Reduction of Endpoints in <z:mp ids='MP_0002057'>NIDDM</z:mp> with the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi> (RENAAL) study </plain></SENT>
<SENT sid="2" pm="."><plain>Renal outcomes were defined as a composite of doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> or <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: At month 6, 259 (38.4%) and 73 (10.8%) patients in the <z:chebi fb="0" ids="6541">losartan</z:chebi> group and 151 (22.8%) and 34 (5.1%) patients in the placebo group had serum <z:chebi fb="120" ids="26216">potassium</z:chebi> ≥5.0 mmol/l and ≥5.5 mmol/l, (p &lt; 0.001), respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> was an independent predictor for serum <z:chebi fb="120" ids="26216">potassium</z:chebi> ≥5.0 mmol/l at month 6 (OR 2.8; 95% CI 2.0-3.9) </plain></SENT>
<SENT sid="5" pm="."><plain>Serum <z:chebi fb="120" ids="26216">potassium</z:chebi> at month 6 ≥ 5.0 mmol/l was in turn associated with increased risk for renal events (HR 1.22; 95% CI 1.00-1.50), independent of other risk factors </plain></SENT>
<SENT sid="6" pm="."><plain>Adjustment of the overall treatment effects for serum <z:chebi fb="120" ids="26216">potassium</z:chebi> augmented <z:chebi fb="0" ids="6541">losartan</z:chebi>'s renoprotective effect from 21% (6-34%) to 35% (20-48%), suggesting that the renoprotective effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> are offset by its effect on serum <z:chebi fb="120" ids="26216">potassium</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: In this study, we found that treatment with the ARB <z:chebi fb="0" ids="6541">losartan</z:chebi> is associated with a high risk of increased serum <z:chebi fb="120" ids="26216">potassium</z:chebi> levels, which is in turn associated with an increased risk of renal outcomes in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Whether additional management of high serum <z:chebi fb="120" ids="26216">potassium</z:chebi> would further increase the renal protective properties of <z:chebi fb="0" ids="6541">losartan</z:chebi> is an important clinical question </plain></SENT>
</text></document>